Meteen naar de inhoud

AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci's AI tech for large-scale protein analysis to find a viable cancer therapy (Michael Peel/Financial Times) 03-12-2023

Michael Peel / Financial Times:
AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy  —  Deal with Absci is the latest between big pharma and tech companies to build new disease treatments


Lees verder op Tech Meme